BridgeBio's acoramidis demonstrated an 18% lower composite risk compared to tafamidis in a real-world study of ATTR-CM patients, with significant reductions in hospitalizations. This data strengthens acoramidis's competitive position against tafamidis, potentially making it the preferred treatment for ATTR-CM and impacting the market share of both drugs.
BridgeBio (BBIO) reported compelling real-world data for its drug acoramidis, showing an 18% lower composite risk and significant hospitalization reductions compared to Pfizer's (PFE) tafamidis in ATTR-CM patients. This is a major positive for BridgeBio, as it validates acoramidis's efficacy in a real-world setting, replicating previous findings and supporting its potential as a 'stabilizer of choice.' For Pfizer, this presents a significant competitive threat to its blockbuster drug, Vyndaqel/Vyndamax (tafamidis), which currently dominates the ATTR-CM market. Short-term, this could lead to increased investor confidence in BBIO and potential downward pressure on PFE's ATTR-CM revenue expectations. Long-term, if acoramidis gains market share, it could significantly alter the treatment landscape for ATTR-CM, posing a key opportunity for BBIO and a risk for PFE.